Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
FDA has approved Xacduro injection (Durlobactam, a new molecular entity in combination with sulbactam) for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia caused by bacteria called Acinetobacter baumannii-calcoaceticus complex
FDA Approves Durbolactam (News Release).
Leave a Comment
You must be logged in to post a comment.